Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Tricida Inc (TCDA) USD0.001

Sell:$36.15 Buy:$36.19 Change: $0.80 (2.26%)
NASDAQ:0.91%
Market closed |  Prices as at close on 21 October 2019 | Switch to live prices |
Sell:$36.15
Buy:$36.19
Change: $0.80 (2.26%)
Market closed |  Prices as at close on 21 October 2019 | Switch to live prices |
Sell:$36.15
Buy:$36.19
Change: $0.80 (2.26%)
Market closed |  Prices as at close on 21 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Tricida, Inc. is a late-stage pharmaceutical company focused on the discovery and clinical development of non-absorbed therapeutics to address renal, metabolic and cardiovascular disease. The Company's lead program, TRC101 is a treatment for chronic kidney disease (CKD). The Company is engaged in developing a non-absorbed drug to enable safety and efficacy for chronic treatment of CKD patients. The TRC101 drug acts in the gastrointestinal tract and clears the human body through the digestive system, by preventing degradation and systemic uptake.

Contact details

Address:
7000 Shoreline Ct Ste 201
SOUTH SAN FRANCISCO
94080-7603
United States
Telephone:
+1 (415) 4297800
Website:
https://www.tricida.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TCDA
ISIN:
US89610F1012
Market cap:
$1.75 billion
Shares in issue:
49.39 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Klaus Veitinger
    Independent Chairman of the Board
  • Gerrit Klaerner
    President, Chief Executive Officer, Director
  • Geoffrey Parker
    Chief Financial Officer, Senior Vice President
  • Wilhelm Stahl
    Senior Vice President, Chief Technology Officer
  • Edward Hejlek
    Senior Vice President, General Counsel
  • Susannah Cantrell
    Senior Vice President, Chief Commercial Officer
  • Claire Lockey
    Senior Vice President and Chief Development Officer
  • Dawn Parsell
    Senior Vice President - Clinical Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.